Abstract Cancer-related anaemia has a number of may even adversely affect the patient's response to cancer treatment. causes, not least the underlying malignancy itself which plays a role in suppressing erythropoiesis. Anaemia is Anaemic cancer patients have a pathophysiology similar to anaemic patients with end-stage renal disoften exacerbated by cancer treatments, in particular routinely used cytotoxic chemotherapy. Chronic anae-ease, in that endogenous erythropoietin is inappropriately low for the degree of anaemia. Such observations mia of cancer is often characterized by inappropriately low levels of endogenous erythropoietin for the degree suggest that therapy with epoetin alfa might offer a means of reversing anaemia in cancer patients. In of anaemia, and manifests clinically with generalized hypoxia and resultant severe fatigue. Epoetin alfa is recent years, there has been a burgeoning interest in the use of epoetin alfa to treat, and possibly to prevent, one recombinant form of erythropoietin, the primary human growth factor responsible for promoting prolif-anaemia associated with both solid tumours and haematological malignancies. This review article sumeration and survival of erythroid progenitor cells. Epoetin alfa has been widely studied for the treatment marizes the background and presents recent findings and progress in this field. of anaemia associated with renal failure and is now recognized as having significant potential in the management of cancer-related anaemia. Studies suggest
Introduction
result of the malignancy itself, and is referred to as 'chronic anaemia of cancer' [1] . Intense interaction In cancer, anaemia is a common haematological abnor-between the tumour cell population and the host's mality arising as a result of contributing factors such as the underlying chronic disease, chemotherapy, radiation therapy or bone marrow invasion with tumour. Table 1 . Causes of cancer-related anaemia. (Adapted from [1] ). Fatigue due to hypoxia is undoubtedly the primary symptom of cancer-related anaemia, causing a signi-The neoplastic process itself-'chronic anaemia of cancer' ficant reduction in physical functioning, mental health Chemotherapy and radiotherapy immune system appears to lead to an increase in the effect and is of value if the anaemia is life-threatening or patients fail to respond adequately to treatment levels of cytokines such as interferon-c, interleukin-1 and tumour necrosis factor [1, 3] . This upsurge of with epoetin. However, blood transfusions carry several recognized risks which must be taken into account inflammatory cytokines brings about a chronic anaemia by suppressing the differentiation of erythroid when deciding on treatment [1] .
Epoetin alfa has been used successfully in recent precursors in the bone marrow, reducing erythropoietin production and preventing normal utilization of iron years to correct or improve symptoms in anaemic cancer patients. It can stimulate erythroid activity and [1] . Additionally, tumour cells produce an 'anaemiainducing substance', thought to be responsible for the is particularly beneficial in those patients with a blunted erythropoietin response to hypoxia [1] . Clinical studies decreased life-span of red blood cells noted in some patients with cancer-related anaemia [1] . Chronic anae-have proved that epoetin alfa can ameliorate the anaemia associated with cancer and chemotherapy, mia of cancer is also exacerbated by chemotherapy [4] .
reduce the need for blood transfusions and improve quality of life [6 ] . For a patient who responds, epoetin Incidence and clinical presentation offers an effective treatment for anaemia; however, not The incidence of chronic anaemia in cancer patients all cancer patients respond well to therapy. depends on malignancy type, stage and duration, treatPatients who are deficient in iron require iron ment regimen and the presence of any intercurrent supplementation, but neither oral nor parenteral iron infection. In colorectal and breast cancer, for example, is particularly effective as monotherapy for the anaemia the prevalence of severe anaemia (haemoglobin of cancer. Iron supplementation combined with epoetiñ 8 g/dl ) is relatively low (10-20%); contrast this with is more effective than iron alone; parenteral iron patients who have non-Hodgkin's lymphoma or mul-administration has been shown to improve the response tiple myeloma, or those receiving chemotherapy for to combined treatment to a greater extent than oral ovarian or lung cancer, where the prevalence appears iron administration [7] . to be far higher (50-60%) [5] .
Anaemia in cancer patients usually manifests clinically as hypoxia-related impairment of virtually every Focus on epoetin
. Symptom severity is dependent on the degree of anaemia, its speed of onset, the underlying Clinical benefits in cancer-related anaemia malignancy and the patient's cardiovascular and pulmonary function. For the patient, severe fatigue, phys-Epoetin alfa can be used to treat patients with symptoical debilitation and resultant feelings of depression matic cancer-related anaemia with the intention of are probably the key symptoms.
relieving symptoms and improving physical performThere is no doubt that symptomatic anaemia and ance and feelings of well-being. Epoetin alfa has also the fatigue it brings can be devastating for a cancer been administered prophylactically in an attempt to patient, whose quality of life will be reduced further prevent or postpone chemotherapy-or radiotherapyon the physical, social and emotional levels [4] .
induced anaemia. Prevention of anaemia during anticancer treatment may enable use of higher doses of chemotherapy and may improve outcome for patients
Management of cancer-related anaemia
undergoing radiotherapy [2] . The available clinical evidence clearly supports the Rationale for treatment use of epoetin alfa to combat cancer-related and chemotherapy-induced anaemia by increasing the All cancer patients with symptomatic anaemia of haematocrit and haemoglobin, decreasing transfusion cancer should be treated in an attempt to offset the requirements and improving quality of life generally detrimental effects of the anaemia on their physical [6 ] . activities, emotional well-being and on the final outImprovement in exercise duration and oxygen concome, particularly in terms of their response to antisumption was demonstrated during epoetin alfa cancer treatments. Despite the obvious rationale, the therapy in patients with anaemia due to renal failure negative impact of anaemia on quality of life for a [8] , and similar findings have been reported in cancer cancer patient often remains underestimated, and many patients. For example, in multiple myeloma patients cancer patients with anaemia who could benefit from who responded to 12 weeks' epoetin alfa treatment, an some form of treatment are managed inadequately, or improvement in performance was noted, based on not at all [1] .
WHO performance criteria [9] . This improvement was not seen in patients who were classed as epoetin alfa Overview of treatment options 'non-responders'. Quality-of-life assessments have also shown a signiTreatment decisions should always be based on symptoms and laboratory findings. Options include the use ficant improvement in mood, appetite and general wellbeing in one group of cancer patients responding to of blood transfusions, iron supplementation and therapy with epoetin alfa.
12 weeks' epoetin alfa treatment. Significant correlations were noted between haemoglobin and degree of Blood transfusion can have an immediate beneficial improvement in mood and appetite (Figure 1) [10]. These findings suggest that achieving haemoglobin within the normal range has a beneficial effect on life quality for patients with cancer-related anaemia [2] .
Use in chemotherapy-induced anaemia
Patients with cancer have been shown to have inappropriately low endogenous erythropoietin for the degree of anaemia. Further suppression of erythropoiesis results from chemotherapy [4] . Epoetin has been studied in the treatment and prevention of chemotherapy-induced anaemia in cancer patients. [4] have investigated the effect of epoetin in treating anaemic cancer patients (with haemoglobin <10.5 g/dl ) categorized as follows:
After the initial double-blind treatment phase, openlabel epoetin alfa could be prescribed with dose incre-$ receiving no chemotherapy; given epoetin alfa 100 ments of 50 IU/kg, to a maximum of 300 IU/kg, IU/kg or placebo subcutaneously (s.c.) three times depending on haemoglobin response. When total epoweekly for 8 weeks.
etin alfa exposure was examined, 40% of the no $ receiving non-cisplatin-based chemotherapy; given chemotherapy group, 56% of the non-cisplatin chemoepoetin alfa 150 IU/kg or placebo s.c. three times therapy group and 58% of the cisplatin chemotherapy weekly for 12 weeks.
group were found to have responded with haematocrit $ receiving cisplatin-based chemotherapy; given epoincreases of >6% unrelated to transfusions. Over 6 etin alfa 150 IU/kg or placebo s.c. three times months of treatment, the corresponding numbers of weekly for 12 weeks.
patients transfused decreased from 31.4 to 10.3% in In these studies, 'response' was defined as improving the no chemotherapy group; from 25.2 to 13% in the the haematocrit by 6% or more, unrelated to transfu-non-cisplatin chemotherapy group and from 42.7 to sion. In each group (no chemotherapy, non-cisplatin 11.5% in the cisplatin chemotherapy group (see chemotherapy, cisplatin chemotherapy), epoetin alfa- Figure 2 ) [4] . treated patients responded to a significantly greater Recently, a large community-based study conducted extent than placebo-treated patients (P<0.008). The by Glaspy et al. [11] investigated the therapeutic improvement in anaemia in all three groups was benefits of epoetin alfa in >2000 patients with anaemia reflected in reduced transfusion requirements in epoetin related to both solid and haematological tumours. alfa-treated patients and in the units transfused per Treatment was administered for a 4 month period at patient. Importantly, transfusions in both groups a dose of 150 IU/kg, given s.c., three times a week; receiving chemotherapy were significantly reduced by the dose could be increased to 300 IU/kg if haematocrit epoetin alfa (P<0.005) when compared with the pla-response proved inadequate [4, 11] . Of the total patient cebo-treated patients. There was also a lag phase before population, 22% were receiving cisplatin-based regithe beneficial effect became apparent ( Figure 2 ) [4] . mens, 18% carboplatin-containing regimens and the remaining 60% were receiving non-cisplatin-based cyclical chemotherapy [4] . Haemoglobin improved significantly (P<0.001) in all tumour response categories, even in patients with progressive disease. Epoetin alfa was associated with a 50% decrease in both the proportion of patients requiring transfusion and the number of units transfused per patient per month ( Figure 3) [4]. Epoetin alfa was also associated with significant increases in mean self-rated scores for energy, activity and overall quality of life; these improvements correlated with the increase in haemoglobin and were independent of tumour response [11] . Epoetin alfa was well tolerated in this study.
The findings from these clinical studies indicate that and quality of life in anaemic cancer patients receiving due to chemotherapy and reduce the prospective need for blood transfusions. A randomized study in patients with small cell lung cancer (receiving up to six cycles of chemotherapy) investigated the benefits of epoetin alfa in preventing anaemia when given at s.c. doses of either 300 or 150 IU/kg, three times a week [4] . Treatment was compared with an untreated control group. Epoetin alfa was given throughout chemotherapy, starting the day after chemotherapy and continuing until 3 days before the next cycle. Epoetin alfa lessened the decline in haemoglobin and reduced the requirement for transfusions in small cell lung cancer patients who initially were non-anaemic and were undergoing primarily cytotoxic chemotherapy [4] .
In another study, 62 early-stage breast cancer patients undergoing six cycles of accelerated adjuvant chemotherapy were randomized to receive either epoetin 150 IU/kg three times a week or no additional treatment. Throughout the chemotherapy, epoetintreated patients maintained stable haemoglobin, whereas control patients developed a progressive anaemia. At the end of chemotherapy, epoetin-treated patients showed a mean decrease in haemoglobin of 0.8 g/dl, compared with 3.05 g/dl in the control group. Clinically significant anaemia (haemoglobin ∏10 g/dl ) was seen in 52% of the control group but in none of the epoetin-treated patients [12] .
Thus, studies have confirmed that epoetin alfa 150 IU/kg, given s.c. three times a week, can effectively treat chemotherapy-induced anaemia in cancer patients and can also help prevent anaemia developing in initially non-anaemic patients receiving cancer chemotherapy. Of key importance is the fact that the epoetininduced improvements in haemoglobin and haematocrit markedly reduce the need for red blood cell transfusions.
Use with high-dose chemotherapy
High-dose chemotherapy followed by bone marrow transplantation (BMT ) or peripheral blood stem cell (PBSC ) support is used increasingly in the treatment of haematological malignancies and some solid tumours [13] . High-dose chemotherapy aims to treat the cancer with a high concentration of chemotherapeutic agents in an attempt to overcome drug resistance problems. Unfortunately, high-dose chemotherapy induces profound myelosuppression as a toxic side effect and, even when prognosis is improved by bone leucopenia, thrombocytopenia and severe anaemia such that packed red blood cell and platelet transfusions frequently are required. cytotoxic chemotherapy. Improvement in functional Following high-dose chemotherapy, anaemia will status is attributable to an increase in haemoglobin, develop and serum erythropoietin will increase, demonstrating that quality of life in these patients can although the course of the anaemia and the changes be improved by treating their anaemia.
in serum erythropoietin are different dependent on whether patients receive allogeneic (genetically differProphylaxis studies. ent) BMT or autologous (patient-donated) BMT [13] . Epoetin in the treatment and prevention of anaemia Epoetin can also be used prophylactically in cancer patients to help prevent the development of anaemia has been studied in these settings.
Epoetin in cancer-related anaemia 89 Treatment with epoetin in the allogeneic BMT recipi-times a week, which was increased incrementally to a maximum of 250 IU/kg if no response was observed ent after high-dose chemotherapy has been found to be effective, whereas treatment in the autologous BMT [9] . A response to epoetin alfa treatment was seen in 11 (85%) patients, who had an increase in haemoglobin recipient has proved disappointing. When outcomes from both allogeneic (n=10) and autologous (n=10) concentration of at least 2 g/dl. The median time to response was 5 weeks. These responders displayed a BMT patients receiving epoetin (75 IU/kg/day for 30 days) after high-dose chemotherapy were compared significant increase in reticulocyte counts without any effect on leucocyte or platelet counts. The bone marrow with matched historical controls, the red blood cell transfusion requirement in the allogeneic BMT recipi-erythropoietic compartment increased by~50%.
Epoetin treatment was well tolerated and improved ents was less than half that of controls (P<0.001), whereas transfusion requirements in autologous BMT quality of life for those who responded.
A number of other studies have confirmed that recipients was similar to controls (P=0.44) [14] .
The efficacy of epoetin in allogeneic BMT recipients epoetin is effective in increasing haemoglobin and correcting anaemia in a significant proportion of has been confirmed in other studies. In one example, 50 patients with haematological malignancies treated patients with lymphoid malignancies [17, 18] . This effect appears independent of concomitant chemotherwith high-dose chemotherapy and allogeneic BMT received either placebo or epoetin, 200 IU/kg/day apy. In all the trials to date, epoetin has proved well tolerated, with no clinically relevant side effects [19] . intravenously (i.v.) for 4 weeks, then 200 IU/kg twice weekly i.v. for the next 4 weeks. Haemoglobin was In particular, these cancer patients did not report the episodes of hypertension sometimes associated with similar in both groups during the study period, but the epoetin-treated patients required fewer blood transfu-epoetin use in patients with anaemia of chronic renal failure. In myeloma patients, monoclonal and other sions to maintain the same haemoglobin compared with patients given placebo (5 RBC U/person vs 10 components have not been affected by epoetin therapy, and no effects on myeloma growth have been noted in RBC U/person respectively, P=0.04) [15] .
Since bone marrow often is unable to respond to any clinical study [19] . epoetin after high-dose chemotherapy in autologous BMT recipients, it may be more effective to administer Chronic lymphocytic leukaemia. epoetin while the marrow is still responsive, i.e. before the chemotherapy. In one small study, patients received Anaemia in patients with chronic lymphocytic leukeither placebo (n=9) or epoetin (n=7), 10 000 IU/day aemia (CLL) is not thought to be the result of inads.c. for 7 days immediately before high-dose chemo-equate erythropoietin production, but is rather due to therapy, then the same dose for 7 days after chemother-haemolysis or splenic sequestration of red blood cells apy. Haemoglobin after chemotherapy was comparable [19] . Despite this, some studies have investigated epoin both groups but the transfusion requirement for the etin for the treatment of anaemia in CLL and have epoetin group was 0.57 RBC U/patient compared with demonstrated benefit in a proportion of these patients 4.0 RBC U/patient in the placebo group (P<0.05) [19] . For example, Rose et al. [20] randomized 221 [16 ] .
anaemic CLL patients into two groups: a placebo Thus, several studies support the use of epoetin to group and a group receiving epoetin alfa 150 IU/kg correct the anaemia associated with allogeneic bone s.c., three times a week for 12 weeks. The chemotherapy marrow transplantation following high-dose chemo-regimen was identical between the two groups. After therapy. In patients receiving autologous bone marrow, 12 weeks' therapy, an increase in haematocrit of at epoetin appears ineffective in the early stages. In least 6% unrelated to transfusion was noted in 47% of delayed anaemia ( later than 30 days after high-dose the epoetin alfa-treated group compared with only chemotherapy), epoetin may be useful in both allo-15% of the placebo group (P<0.001). Thirty two geneic and autologous BMT recipients [13] . When percent of the epoetin alfa-treated patients reached a given before high-dose chemotherapy, epoetin can haematocrit of at least 38% compared with only 5% in reduce transfusion requirements before significant the placebo group (P<0.001). Units transfused were myelosuppression occurs and there is also some evid-significantly reduced in epoetin-treated patients vs plaence to suggest that epoetin may help mobilize eryth-cebo. Quality of life (measured by energy, self-rated roid progenitor cells and other precursor cells in this health, physical and social function and mental health) setting [13] . Thus, epoetin has an important role to was significantly improved in patients who reached a play in the treatment of anaemia associated with high-haematocrit of 38%. dose chemotherapy.
Despite the positive findings from this study, the long-term response, optimal dose regimen and predictors of response remain to be determined for this Use in anaemia associated with haematological particular patient group.
cancers

Myelodysplastic syndromes. Myeloma and lymphoid malignancies.
Myelodysplastic syndromes (MDS) are a specific type One initial study in a group of 13 anaemic myeloma patients used epoetin alfa at a dose of 150 IU/kg three of haematological malignancy, occurring mainly in the elderly. Approximately two-thirds of MDS patients >14 g/dl in 80% of the epoetin alfa-treated group compared with only 5% of the control group present with anaemia, and nearly all experience anaemia during the course of their disease, often becoming (P<0.001). Epoetin alfa treatment had no significant effect on blood pressure, white blood cell, neutrophil transfusion-dependent. The pathogenesis of the anaemia in MDS is complex; erythroid progenitors are or platelet counts, or liver or renal function. This study showed that epoetin alfa, with ferrous sulfate, appears defective for their proliferation and maturation, and patients often have high endogenous serum erythro-to be an effective means of increasing red cell mass during radiotherapy [24] . Further work is required to poietin, which is not usual in other cancer-related anaemias.
determine whether tumour control by radiotherapy is enhanced by adjuvant treatment with epoetin. Theoretically, there is a rationale for treating MDS patients with epoetin in an attempt to overcome the defective proliferation with pharmacological doses of Patient selection for treatment epoetin. However, studies have shown rather low
The selection of cancer patients for treatment with responses to epoetin alone (15-40% response) [21] .
epoetin is regarded as mandatory [2], because Combinations with cytokines, such as recombinant~5 0-60% of unselected patients respond well to treathuman granulocyte colony-stimulating factor, have ment [2, 3] . A 'response' to epoetin is usually defined been tested [22, 23] , but further studies are required to in terms of normalization of the haematocrit in determine fully whether such combinations might anaemic cancer patients, or maintenance of a normal increase response rates in selected MDS patients.
haematocrit where epoetin is given to prevent anaemia during chemotherapy [3] . As well as avoidance of Use with radiotherapy blood transfusion in MDS patients, there is certainly a clear dose-response effect with epoetin [3], but doses Anaemic cancer patients have been found to demonutilized in cancer patients typically have been higher strate a poorer response to cancer treatment, particu-(in the range 450-900 IU/kg/week) than those recomlarly radiotherapy, when compared with non-anaemic mended in renal failure patients [3] . Responsiveness, patients. Haemoglobin during radiotherapy is positthen, appears to vary between patients and disease ively correlated with patient survival and local control categories, depending on a range of influencing factors. of certain tumour types [24, 25] . Haemoglobin has been
The prediction of response to treatment is, however, shown to be a predictor of disease-free and/or overall feasible. survival after radiotherapy for cervical and head/neck cancers, independently of other variables [25] . Work has also suggested that a low haemoglobin specifically Variable response. decreases the efficacy of radiation therapy [24] . It has
The response to epoetin in the treatment of cancerbeen postulated that this lack of effect, or 'radioresistrelated anaemia has been linked to baseline haematoance', of the tumour cells results from tissue hypoxia crit, transfusion needs [4] and tumour type [2], with [25] . In other words, maintenance of normal tissue high response rates noted in patients with head/neck oxygenation is necessary to prevent an impaired cancers, lung cancer, other squamous cell carcinomas response to radiotherapy and improve treatment or lymphoproliferative disorders ( Figure 4) [2]. outcome.
However, the influence of tumour type is likely to be One early study demonstrated that red blood cell transfusion prior to pelvic radiotherapy significantly increased the disease-free survival rates of anaemic patients to the level of that of non-anaemic patients [24, 25] . The recognition of a clear association between haemoglobin and tumour control by radiation therapy has resulted, in some centres, in severely anaemic cancer patients being transfused routinely prior to a course of radiotherapy. Treatment with epoetin is another possible option.
One study has assessed the effects of epoetin alfa on haemoglobin in 40 patients with a baseline haemoglobin of <13.5 g/dl, scheduled to undergo a 5-8 week course of daily radiation therapy for a solid tumour without metastases [24] . All patients received oral iron and half the group were also given epoetin 150-300 IU/kg s.c. three times a week, beginning 0-10 days prior to the first dose of radiation. All the patients treated with epoetin alfa demonstrated an increase of >6% in haemoglobin during radiotherapy, compared During therapy, haemoglobin rose to a mean of significant only when there is major marrow involve-increase by at least 0.5 g/dl, a lack of response can be ment and reduced residual haematopoiesis, or if specific predicted with 93% accuracy and epoetin treatment mechanisms for anaemia exist (e.g. haemolysis, spleno-should be discontinued [2] . megaly, bleeding) [4] .
These, and various other, outcome prediction models Chemotherapy-and/or radiotherapy-induced anae-for epoetin treatment offer the means to ensure costmia appear to respond well to epoetin [2] , although it effective use of this agent by providing it to as many is thought that lower response rates can be expected anaemic cancer patients as possible, with a high chance in patients receiving more intensive chemotherapy regi-of a success. Patients should be monitored for infecmens [3] . Complications of chemotherapy, such as tions, functional iron deficiency and other factors that inflammation, infections, nutritional deficiencies or may act to reduce a high predicted response to epobleeding, may have a negative impact on response to etin [3] . epoetin [3] .
Functional iron deficiency, diagnosed as a percentage of hypochromic red blood cells >10% and/or transferrin saturation <15%, is a major factor limiting response to epoetin therapy. However, since there is Conclusions concern that some tumour cells require iron for maximal growth, routine iron supplementation of all cancer Symptomatic anaemia of cancer can cause severe patients receiving epoetin is not recommended, unless fatigue and a significantly impaired quality of life for absolute iron deficiency is present [3] . Iron supplements the patient. Often, this negative impact of anaemia is can be given until the percentage of hypochromic red underestimated and cancer patients with anaemia are blood cells returns to normal. poorly managed. Typically, patients with cancer have The response to epoetin in cancer patients can be inappropriately low concentrations of endogenous slow to develop; for instance, significant differences in erythropoietin for the degree of anaemia and further transfusion requirements between epoetin-and pla-suppression of endogenous erythropoiesis can be cebo-treated patients may become apparent after the induced by cytokines used for chemotherapy. Thus, first month of treatment [3] . Response can be main-epoetin offers a potentially beneficial therapy for tained for a year or more, although transient loss of cancer-related anaemia. responsiveness has been noted under certain circumClinical studies have shown that epoetin alfa (150 stances, for example intercurrent infection, inflamma-IU/kg three times a week) effectively treats a proportion, surgery or progression of the underlying cancer tion of patients with symptomatic anaemia of cancer [2] . and can prevent or reduce treatment-induced anaemia in patients undergoing cancer chemotherapy. Epoetin Predicting response.
increases haemoglobin concentration and the haematocrit, reduces the need for blood transfusions and signiAs noted previously,~50-60% of anaemic cancer ficantly improves quality of life as a direct result. The patients respond well to epoetin therapy [2, 3] and efficacy of epoetin in the treatment of the anaemia response to treatment can take weeks to become clinicwhich develops in the setting of high-dose chemotherally apparent; up to 4-8 weeks' epoetin therapy may apy with allogeneic bone marrow transplantation has be needed to rule out responsiveness in a given patient been demonstrated. Epoetin has also been used with [2] . Such treatment may be costly and non-productive success to treat anaemia in a range of haematological in a non-responsive patient, hence the focus has been cancers, including the atypical anaemia associated with on developing reliable parameters for the prediction of CLL and, when therapy is combined with other growth response to epoetin in individual cancer patients.
factors, in MDS. There have been two main approaches to predicting Anaemia of cancer has been associated with impaired response. Firstly, analyses have been conducted to tumour response to radiotherapy. Normalization of determine whether serum erythropoietin is lower than haemoglobin in anaemic cancer patients has been anticipated, based on the patient's haemoglobin (the shown to improve local tumour control and diseasedegree of blunted erythropoietin response) [2, 3] . free survival after curative radiation treatment. Secondly, analyses were done to measure predictability Treatment with epoetin may help improve the tumour of indicators of erythropoietic marrow responsiveness response to radiotherapy in certain settings. (such as increases in haemoglobin, reticulocyte count, It is important to recognize that even 50-60% of soluble transferrin receptors or serum ferritin) in the unselected cancer patients respond adequately to epoinitial stages of epoetin treatment [2, 3] .
etin. Thus, careful patient selection according to reliOne useful predictive model based on measurement able prediction criteria is vital to ensure optimum of erythropoietin and haemoglobin has shown that if, clinical use of this therapy. after 2 weeks of treatment with epoetin, serum erythroWith all these facts in mind, the therapeutic, or poietin is <100 mU/ml and haemoglobin has increased prophylactic, use of epoetin should always be considby >0.5 g/dl, a response to epoetin can be predicted ered as an important component of the overall care with 95% accuracy. Conversely, if serum erythropoietin exceeds 100 mU/ml and haemoglobin has failed to for cancer patients.
